Accessibility Menu
Dynavax Technologies logo

Dynavax Technologies(NASDAQ) DVAX

This security has been delisted. This page is retained for historical reference.

Dynavax Technologies last closing stock price
MetricPriceDate
Last closeUSD 15.502026-02-09
Dynavax Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.06%USD 15.492026-02-02
1 month+0.58%USD 15.412026-01-09
3 month+37.53%USD 11.272025-11-11
Year to date+0.78%USD 15.382025-12-31
1 year+17.87%USD 13.152025-02-07
3 year+40.27%USD 11.052023-02-10
5 year+57.84%USD 9.822021-02-10
Since inception-83.51%USD 94.002004-02-19

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

DVAX Financials

Key Financial Metrics (TTM)

Gross Margin

83.67%

Operating Margin

4.67%

Net Income Margin

-19.52%

Return on Equity

-9.71%

Return on Capital

-0.48%

Return on Assets

-5.33%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$274.90M

Operating Income

$10.44M

EBITDA

-$25.65M

Operating Cash Flow

$90.63M

Capital Expenditure

-$10.10M

Free Cash Flow

$80.54M

Cash & ST Invst.

$647.82M

Total Debt

$289.22M

Dynavax Technologies Performance Analysis

Dynavax Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 437,042,000N/A
20222022-12-31USD 722,683,00065.4%
20232023-12-31USD 232,284,000-67.9%
20242024-12-31USD 277,246,00019.4%
Dynavax Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-10.7%
Q12025-03-31-5.4%
Q22025-06-3040.0%
Q32025-09-30-0.6%
Dynavax Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD 0.54N/A
20222022-12-31USD 1.97262.4%
20232023-12-31USD -0.05N/A
20242024-12-31USD 0.20N/A
Dynavax Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-58.1%
Q12025-03-31-1770.3%
Q22025-06-30118.2%
Q32025-09-3050.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$94.88M

+17.7%

Gross Profit

$80.47M

+19.1%

Gross Margin

84.82%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

405

N/A

Net Income

$26.93M

+53.0%

EBITDA

$31.89M

+35.3%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$647.82M

-15.2%

Total Debt

$289.22M

+13.6%

Accounts Receivable

$73.32M

-2.6%

Inventory

$73.29M

+17.4%

Long Term Debt

$244.95M

-2.1%

Short Term Debt

$44.27M

+900.9%

Return on Assets

-5.33%

N/A

Return on Invested Capital

1.44%

N/A

Free Cash Flow

$32.59M

+79.9%

Operating Cash Flow

$33.83M

+73.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMPHAmphastar Pharmaceuticals, Inc.
$19.94-2.16%
COLLCollegium Pharmaceutical, Inc.
$35.39-1.64%
BBNXBeta Bionics, Inc.
$12.83-10.09%
PCRXPacira BioSciences, Inc.
$26.41-2.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.